Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endpoint Enabling Study of Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD)

NCT05373719 is registered in ClinicalTrials.gov with Loulou Foundation as lead sponsor.

NCT NCT05373719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05373719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endpoint Enabling Study of Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD)
Lead sponsor
Loulou Foundation
Phase
Observational
Overall status
Active, not recruiting
Start date
September 30, 2022
Completion date
January 20, 2027
Enrollment
112 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cyclin-dependent kinase-like 5 deficiency disorder